Do analysts prefer GDTC or GOSS?

Gossamer Bio has a consensus price target of $3.20, suggesting a potential upside of 1,722.32%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22

Which has better earnings and valuation, GDTC or GOSS?

CytoMed Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CytoMed Therapeutics $250K 42.26 -$3.10M N/A N/A Gossamer Bio $48.47M 0.85 -$170.37M -$0.70 N/A

Is GDTC or GOSS more profitable?

CytoMed Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Company Net Margins Return on Equity Return on Assets CytoMed Therapeutics N/A N/A N/A Gossamer Bio -235.00% N/A -112.04%

Do analysts rate RNAZ or GDTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, RNAZ or GDTC?

CytoMed Therapeutics has higher revenue and earnings than TransCode Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A CytoMed Therapeutics $250K 42.26 -$3.10M N/A N/A

Is RNAZ or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% CytoMed Therapeutics N/A N/A N/A

Which has higher valuation & earnings, RADX or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 16.54 -$24.83M N/A N/A CytoMed Therapeutics $250K 42.26 -$3.10M N/A N/A

Is RADX or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A CytoMed Therapeutics N/A N/A N/A

Do analysts rate GDTC or MDXH?

MDxHealth has a consensus price target of $2.17, suggesting a potential upside of 198.36%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has higher valuation & earnings, GDTC or MDXH?

CytoMed Therapeutics has higher earnings, but lower revenue than MDxHealth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CytoMed Therapeutics $250K 42.26 -$3.10M N/A N/A MDxHealth $107.88M 0.33 -$33.52M -$0.72 N/A

Is GDTC or MDXH more profitable?

CytoMed Therapeutics has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Company Net Margins Return on Equity Return on Assets CytoMed Therapeutics N/A N/A N/A MDxHealth -33.46% N/A -24.25%

Do analysts rate CNTX or GDTC?

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 1,598.81%. Given Context Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Context Therapeutics is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, CNTX or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Context Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A CytoMed Therapeutics $250K 42.26 -$3.10M N/A N/A

Is CNTX or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% CytoMed Therapeutics N/A N/A N/A

CytoMed Therapeutics (GDTC) Competitors

$0.89 +0.01 (+1.48%)

As of 09/3/2026 12:29 PM Eastern

Compare

GDTC vs. GOSS, RNAZ, RADX, MDXH, and CNTX

Should you buy CytoMed Therapeutics stock or one of its competitors? CytoMed Therapeutics's main competitors and comparable companies include Gossamer Bio (GOSS), TransCode Therapeutics (RNAZ), Radiopharm Theranostics (RADX), MDxHealth (MDXH), and Context Therapeutics (CNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CytoMed Therapeutics compare to Gossamer Bio?

CytoMed Therapeutics (NASDAQ:GDTC) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

CytoMed Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Gossamer Bio	-235.00%	N/A	-112.04%

CytoMed Therapeutics has higher earnings, but lower revenue than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	42.26	-$3.10M	N/A	N/A
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.70	N/A

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CytoMed Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

In the previous week, Gossamer Bio had 10 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 10 mentions for Gossamer Bio and 0 mentions for CytoMed Therapeutics. Gossamer Bio's average media sentiment score of 0.20 beat CytoMed Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
CytoMed Therapeutics	Neutral
Gossamer Bio	Neutral

Gossamer Bio has a consensus price target of $3.20, suggesting a potential upside of 1,722.32%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Gossamer Bio beats CytoMed Therapeutics on 9 of the 13 factors compared between the two stocks.

How does CytoMed Therapeutics compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

In the previous week, TransCode Therapeutics had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for TransCode Therapeutics and 0 mentions for CytoMed Therapeutics. TransCode Therapeutics' average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
CytoMed Therapeutics	Neutral

TransCode Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

0.0% of CytoMed Therapeutics shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CytoMed Therapeutics has higher revenue and earnings than TransCode Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
CytoMed Therapeutics	$250K	42.26	-$3.10M	N/A	N/A

CytoMed Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
CytoMed Therapeutics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CytoMed Therapeutics beats TransCode Therapeutics on 5 of the 8 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Radiopharm Theranostics had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Radiopharm Theranostics and 0 mentions for CytoMed Therapeutics. Radiopharm Theranostics' average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
CytoMed Therapeutics	Neutral

CytoMed Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	16.54	-$24.83M	N/A	N/A
CytoMed Therapeutics	$250K	42.26	-$3.10M	N/A	N/A

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 411.63%. Given Radiopharm Theranostics' stronger consensus rating and higher possible upside, research analysts clearly believe Radiopharm Theranostics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
CytoMed Therapeutics	N/A	N/A	N/A

Radiopharm Theranostics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

Summary

Radiopharm Theranostics beats CytoMed Therapeutics on 6 of the 9 factors compared between the two stocks.

How does CytoMed Therapeutics compare to MDxHealth?

CytoMed Therapeutics (NASDAQ:GDTC) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

CytoMed Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

MDxHealth has a consensus price target of $2.17, suggesting a potential upside of 198.36%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

CytoMed Therapeutics has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
MDxHealth	-33.46%	N/A	-24.25%

0.0% of CytoMed Therapeutics shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CytoMed Therapeutics has higher earnings, but lower revenue than MDxHealth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	42.26	-$3.10M	N/A	N/A
MDxHealth	$107.88M	0.33	-$33.52M	-$0.72	N/A

In the previous week, MDxHealth had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for MDxHealth and 0 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score.

Company	Overall Sentiment
CytoMed Therapeutics	Neutral
MDxHealth	Neutral

Summary

MDxHealth beats CytoMed Therapeutics on 7 of the 12 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 1,598.81%. Given Context Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Context Therapeutics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
CytoMed Therapeutics	N/A	N/A	N/A

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CytoMed Therapeutics has higher revenue and earnings than Context Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
CytoMed Therapeutics	$250K	42.26	-$3.10M	N/A	N/A

In the previous week, Context Therapeutics had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Context Therapeutics and 0 mentions for CytoMed Therapeutics. Context Therapeutics' average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Context Therapeutics	Neutral
CytoMed Therapeutics	Neutral

Context Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Summary

Context Therapeutics beats CytoMed Therapeutics on 7 of the 11 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDTC vs. The Competition

Export

Metric	CytoMed Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.41M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	N/A	12.66	273.29	25.38
Price / Sales	42.26	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.98	16.29	12.89	6.14
Net Income	-$3.10M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.93%	0.34%	0.60%	-0.27%
1 Month Performance	4.80%	8.52%	5.73%	0.68%
1 Year Performance	-53.00%	52.66%	25.35%	14.84%

CytoMed Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDTC CytoMed Therapeutics	0.4208 of 5 stars	$0.89 +1.5%	N/A	-54.3%	$10.41M	$250K	N/A	N/A	Gap Down
GOSS Gossamer Bio	2.566 of 5 stars	$0.17 -1.8%	$3.20 +1,816.2%	-93.2%	$39.20M	$48.47M	N/A	180
RNAZ TransCode Therapeutics	0.1382 of 5 stars	$2.22 -2.6%	N/A	-79.5%	$37.59M	N/A	N/A	9	News Coverage Gap Up
RADX Radiopharm Theranostics	2.3415 of 5 stars	$2.48 +9.7%	$11.00 +343.5%	-60.9%	$35.86M	$2.35M	N/A	N/A	Gap Down High Trading Volume
MDXH MDxHealth	2.018 of 5 stars	$0.72 -0.2%	$2.17 +200.9%	-79.8%	$35.64M	$114.02M	N/A	300	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDTC) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. GOSS, RNAZ, RADX, MDXH, and CNTX

How does CytoMed Therapeutics compare to Gossamer Bio?

Summary

How does CytoMed Therapeutics compare to TransCode Therapeutics?

Summary

How does CytoMed Therapeutics compare to Radiopharm Theranostics?

Summary

How does CytoMed Therapeutics compare to MDxHealth?

Summary

How does CytoMed Therapeutics compare to Context Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. GOSS, RNAZ, RADX, MDXH, and CNTX

How does CytoMed Therapeutics compare to Gossamer Bio?

Is GDTC or GOSS more profitable?

Which has better earnings and valuation, GDTC or GOSS?

Do institutionals and insiders hold more shares of GDTC or GOSS?

Which has more volatility and risk, GDTC or GOSS?

Does the media prefer GDTC or GOSS?

Do analysts prefer GDTC or GOSS?

Summary

How does CytoMed Therapeutics compare to TransCode Therapeutics?

Does the media favor RNAZ or GDTC?

Which has more volatility and risk, RNAZ or GDTC?

Do institutionals & insiders have more ownership in RNAZ or GDTC?

Which has stronger earnings & valuation, RNAZ or GDTC?

Is RNAZ or GDTC more profitable?

Do analysts rate RNAZ or GDTC?

Summary

How does CytoMed Therapeutics compare to Radiopharm Theranostics?

Do insiders & institutionals have more ownership in RADX or GDTC?

Does the media favor RADX or GDTC?

Which has higher valuation & earnings, RADX or GDTC?

Do analysts prefer RADX or GDTC?

Is RADX or GDTC more profitable?

Which has more risk and volatility, RADX or GDTC?

Summary

How does CytoMed Therapeutics compare to MDxHealth?

Which has more risk and volatility, GDTC or MDXH?

Do analysts rate GDTC or MDXH?

Is GDTC or MDXH more profitable?

Do institutionals and insiders have more ownership in GDTC or MDXH?

Which has higher valuation & earnings, GDTC or MDXH?

Does the media refer more to GDTC or MDXH?

Summary

How does CytoMed Therapeutics compare to Context Therapeutics?

Do analysts rate CNTX or GDTC?

Is CNTX or GDTC more profitable?

Do insiders & institutionals hold more shares of CNTX or GDTC?

Which has higher earnings & valuation, CNTX or GDTC?

Does the media favor CNTX or GDTC?

Which has more risk & volatility, CNTX or GDTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools